Literature DB >> 35948751

Tax1 banding protein 1 exacerbates heart failure in mice by activating ITCH-P73-BNIP3-mediated cardiomyocyte apoptosis.

Qing-Qing Wu1,2,3, Qi Yao1,2,3, Tong-Tong Hu1,2,3, Ying Wan1,2,3, Qing-Wen Xie1,2,3, Jin-Hua Zhao1,2,3, Yuan Yuan1,2,3, Qi-Zhu Tang4,5,6.   

Abstract

Tax1 banding protein 1 (Tax1bp1) was originally identified as an NF-κB regulatory protein that participated in inflammatory, antiviral and innate immune processes. Tax1bp1 also functions as an autophagy receptor that plays a role in autophagy. Our previous study shows that Tax1bp1 protects against cardiomyopathy in STZ-induced diabetic mice. In this study we investigated the role of Tax1bp1 in heart failure. Pressure overload-induced heart failure model was established in mice by aortic banding (AB) surgery, and angiotensin II (Ang II)-induced heart failure model was established by infusion of Ang II through osmotic minipump for 4 weeks. We showed that the expression levels of Tax1bp1 in the heart were markedly increased 2 and 4 weeks after AB surgery. Knockdown of Tax1bp1 in mouse hearts significantly ameliorated both AB- and Ang II infusion-induced heart failure parameters. On the contrary, AB-induced heart failure was aggravated in cardiac-specific Tax1bp1 transgenic mice. Similar results were observed in neonatal rat cardiomyocytes (NRCMs) under Ang II insult. We demonstrated that the pro-heart failure effect of Tax1bp1 resulted from its interaction with the E3 ligase ITCH to promote the transcription factor P73 ubiquitination and degradation, causing enhanced BCL2 interacting protein 3 (BNIP3)-mediated cardiomyocyte apoptosis. Knockdown ITCH or BNIP3 in NRCMs significantly reduced Ang II-induced apoptosis in vitro. Similarly, BNIP3 knockdown attenuated heart failure in cardiac-specific Tax1bp1 transgenic mice. In the left ventricles of heart failure patients, Tax1bp1 expression level was significantly increased; Tax1bp1 gene expression was negatively correlated with left ventricular ejection fraction in heart failure patients. Collectively, the Tax1bp1 increase in heart failure enhances ITCH-P73-BNIP3-mediated cardiomyocyte apoptosis and induced cardiac injury. Tax1bp1 may serve as a potent therapeutic target for the treatment of heart failure.• Cardiac Tax1bp1 transgene mice were more vulnerable to cardiac dysfunction under stress.• Cardiac Tax1bp1 transgene mice were more vulnerable to cardiac dysfunction under stress.• Knockout of Tax1bp1 in mouse hearts ameliorated heart failure induced by pressure overload.• Tax1bp1 interacts with the E3 ligase Itch to promote P73 ubiquitination and degradation, causing enhanced BNIP3-mediated apoptosis.• Tax1bp1 may become a target of new therapeutic methods for treating heart failure.
© 2022. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society.

Entities:  

Keywords:  BCL2 interacting protein 3; ITCH; P73; Tax1 banding protein 1; apoptosis; heart failure

Mesh:

Substances:

Year:  2022        PMID: 35948751      PMCID: PMC9525615          DOI: 10.1038/s41401-022-00950-2

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   7.169


  36 in total

Review 1.  Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease.

Authors:  Guanghong Jia; Adam Whaley-Connell; James R Sowers
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

Review 2.  Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease.

Authors:  Dominic P Del Re; Dulguun Amgalan; Andreas Linkermann; Qinghang Liu; Richard N Kitsis
Journal:  Physiol Rev       Date:  2019-10-01       Impact factor: 37.312

3.  The Ubiquitin Binding Protein TAX1BP1 Mediates Autophagasome Induction and the Metabolic Transition of Activated T Cells.

Authors:  Michael I Whang; Rita M Tavares; Daniel I Benjamin; Michael G Kattah; Rommel Advincula; Daniel K Nomura; Jayanta Debnath; Barbara A Malynn; Averil Ma
Journal:  Immunity       Date:  2017-03-14       Impact factor: 31.745

Review 4.  Mechanisms contributing to cardiac remodelling.

Authors:  Qing-Qing Wu; Yang Xiao; Yuan Yuan; Zhen-Guo Ma; Hai-Han Liao; Chen Liu; Jin-Xiu Zhu; Zheng Yang; Wei Deng; Qi-Zhu Tang
Journal:  Clin Sci (Lond)       Date:  2017-08-24       Impact factor: 6.124

5.  TAX1BP1 and A20 inhibit antiviral signaling by targeting TBK1-IKKi kinases.

Authors:  Kislay Parvatiyar; Glen N Barber; Edward W Harhaj
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

6.  Cathepsin B deficiency attenuates cardiac remodeling in response to pressure overload via TNF-α/ASK1/JNK pathway.

Authors:  Qing-Qing Wu; Man Xu; Yuan Yuan; Fang-Fang Li; Zheng Yang; Yuan Liu; Meng-Qiao Zhou; Zhou-Yan Bian; Wei Deng; Lu Gao; Hongliang Li; Qi-Zhu Tang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-20       Impact factor: 4.733

Review 7.  Role of BNIP3 and NIX in cell death, autophagy, and mitophagy.

Authors:  J Zhang; P A Ney
Journal:  Cell Death Differ       Date:  2009-02-20       Impact factor: 15.828

Review 8.  Heart failure.

Authors:  Eugene Braunwald
Journal:  JACC Heart Fail       Date:  2013-02-04       Impact factor: 12.035

9.  Loss of TAX1BP1-Directed Autophagy Results in Protein Aggregate Accumulation in the Brain.

Authors:  Shireen A Sarraf; Hetal V Shah; Gil Kanfer; Alicia M Pickrell; Lynne A Holtzclaw; Michael E Ward; Richard J Youle
Journal:  Mol Cell       Date:  2020-11-17       Impact factor: 17.970

10.  Commensal microbiota contributes to chronic endocarditis in TAX1BP1 deficient mice.

Authors:  Satoko Nakano; Emi Ikebe; Yoshiyuki Tsukamoto; Yan Wang; Takashi Matsumoto; Takahiro Mitsui; Takaaki Yahiro; Kunimitsu Inoue; Hiroaki Kawazato; Aiko Yasuda; Kanako Ito; Shigeo Yokoyama; Naohiko Takahashi; Mitsuo Hori; Tatsuo Shimada; Masatsugu Moriyama; Toshiaki Kubota; Katsushige Ono; Wataru Fujibuchi; Kuan-Teh Jeang; Hidekatsu Iha; Akira Nishizono
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.